NVS-CECR2-1
NVS-CECR2-1, a non-BET family Bromodomain (BRD) inhibitor, is a potent and selective cat eye syndrome chromosome region, candidate 2 (CECR2) inhibitor. NVS-CECR2-1 binds to CECR2 BRD with high affinity (IC50=47 nM; KD=80 nM) . NVS-CECR2-1 exhibits cytotoxic activity and induces apoptosis against various cancer cells by targeting CECR2 as well as via CECR2-independent mechanism[1]. NVS-CECR2-1 is a chemical probe.
Product Specifications
CAS Number
[1992047-61-6]
UNSPSC
12352005
Target
Apoptosis; Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nvs-cecr2-1.html
Purity
99.40
Solubility
DMSO : 66.67 mg/mL (ultrasonic)
Smiles
CC1(C)CC(N2C=CC3=C2C=CC(C4=CC(NC5CC5)=NC(S(=O)(CCC)=O)=N4)=C3)CC(C)(C)N1
Molecular Formula
C27H37N5O2S
Molecular Weight
495.68
References & Citations
[1]Seul Gi Park, et al. Cytotoxic activity of bromodomain inhibitor NVS-CECR2-1 on human cancer cells. Sci Rep. 2020 Oct 1;10 (1) :16330.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4; BRD7; BRD9; CECR2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
DHX32 (Putative Pre-mRNA-splicing Factor ATP-dependent RNA Helicase DHX32, DEAD/H Box 32, DEAD/H Helicase-like Protein 1, DHLP1, DEAH Box Protein 32, HuDDX32, DDX32) (MaxLight 550)
